00:26 , Jul 20, 2019 |  BC Extra  |  Clinical News

July 19 Clinical Quick Takes: Polyphor closes Phase III murepavadin trials; plus Takeda and Alector

Polyphor ends PRISM trials  The Swiss immuno-oncology company Polyphor AG (SIX:POLN) closed the Phase III PRISM MDR and PRISM UDR trials of its IV formulation of murepavadin for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) after...
22:39 , Jul 9, 2019 |  BC Extra  |  Company News

July 9 Company Quick Takes: Celgene, Nimbus expand deal; plus Gilead-Lyndra, Darzalex and more

Celgene gets option for Nimbus' HPK1 program  Celgene Corp. (NASDAQ:CELG) expanded its partnership with Nimbus Therapeutics LLC (Cambridge, Mass.) to include an option for the latter's HPK1 inhibitor to treat cancer, which Celgene can exercise...
01:33 , Apr 19, 2019 |  BC Innovations  |  Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

Working in the background, while amyloid therapies have floundered, has been a group of companies betting that the immune system can do for neurodegeneration what it is has done for oncology. The first wave of...
12:44 , Mar 21, 2019 |  BC Innovations  |  Emerging Company Profile

A Passage to optimal CNS vectors

Passage is arming itself with AAV vectors, gene therapies and non-human primate studies from gene therapy pioneer James Wilson at UPenn to develop disease-modifying treatments for rare monogenic diseases affecting the CNS. The company launched...
01:56 , Feb 8, 2019 |  BC Week In Review  |  Financial News

Immuno-neurology company Alector dips after $175.8M IPO

Alector Inc. (NASDAQ:ALEC) raised $175.8 million in an IPO to support clinical trials of a handful of antibodies for neurologic indications including frontotemporal dementia and Alzheimer's disease. The immuno-neurology company sold 9.3 million shares at...
03:46 , Feb 7, 2019 |  BC Extra  |  Company News

Immuno-neurology company Alector dips after $175.8M IPO

Alector Inc. (NASDAQ:ALEC) shares fell $1 to $18 Thursday after the company raised $175.8 million in an IPO to support clinical trials of a handful of antibodies for neurologic indications including frontotemporal dementia and Alzheimer's...
17:34 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Alector, Poseida and Anchiano propose NASDAQ listings

Alector Inc. (South San Francisco, Calif.), Poseida Therapeutics Inc. (San Diego, Calif.) and Anchiano Therapeutics Inc. (Tel Aviv:ANCN) have proposed to list on NASDAQ. Alector, which aims to target immune dysfunction to treat neurodegenerative disorders,...
04:39 , Jan 8, 2019 |  BC Extra  |  Financial News

Alector, Poseida and Anchiano propose NASDAQ listings

Alector Inc. (South San Francisco, Calif.), Poseida Therapeutics Inc. (San Diego, Calif.) and Anchiano Therapeutics Inc. (Tel Aviv:ANCN) have proposed to list on NASDAQ. Alector, which aims to target immune dysfunction to treat neurodegenerative disorders,...
16:39 , Oct 26, 2018 |  BC Week In Review  |  Company News

Dementia Discovery Fund, UK Dementia Research Institute partner to fund dementia research

The Dementia Discovery Fund (DDF) and UK Dementia Research Institute launched a partnership dubbed D3A to grant multiple awards of £100,000-£200,000 ($130,768-$261,536) to support clinical translation. D3A will fund translational projects from UK Dementia Research...
17:18 , Oct 24, 2018 |  BC Extra  |  Company News

Dementia Discovery Fund, UK Dementia Research Institute partner to fund dementia research

The Dementia Discovery Fund (DDF) and UK Dementia Research Institute launched a partnership dubbed D3A to grant multiple awards of £100,000-£200,000 ($130,768-$261,536) to support clinical translation. D3A will fund translational projects from UK Dementia Research...